RBC Capital and Mizuho Securities Stay Bullish on Surgery Partners (SGRY)

Surgery Partners, Inc. (NASDAQ:SGRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 19, RBC Capital reiterated its Buy rating on Surgery Partners, Inc. (NASDAQ:SGRY) with a price target of $31 on the stock. The research firm believes that the company’s long-term growth prospects are still intact.

Earlier, on December 18, Mizuho Securities reduced its price target on Surgery Partners, Inc. (NASDAQ:SGRY) from $22 to $19 but kept its Outperform rating on the shares. This update was part of the research firm’s 2026 outlook for managed care and health facilities.

Mizuho Securities believes that 2026 will prove to be a “pivotal year” for the sector. The firm noted that the sector is coming out of a three-year negative underwriting cycle. The firm’s analyst told investors in a research note that margins are expected to improve across commercial insurance, Medicaid, and Medicare over the coming years. Even after lowering its price target on Surgery Partners, Inc. (NASDAQ:SGRY), Mizuho Securities remains positive on managed care heading into 2026.

Surgery Partners, Inc. (NASDAQ:SGRY) is a leading healthcare services company that operates a network of more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices, and urgent care facilities.

While we acknowledge the potential of SGRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best US Penny Stocks to Buy and 10 Best New Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.